High Altitude Pulmonary Hypertension, Sleep Apnea
Conditions
Keywords
high altitude illness, pulmonary hypertension, sleep apnea, disease progression, hypoxia
Brief summary
The purpose of the current study is to evaluate the clinical and physiologic course of Kyrgyz highlanders with high altitude pulmonary hypertension (HAPH) by performing a longitudinal cohort study. To this end, the investigators will invite the same highlanders who participated in the study in 2012 to undergo follow-up examinations in 2017, in order to allow comparisons of current results with baseline data from 2012.
Interventions
None listed
Sponsors
National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
University of Zurich
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* high altitude pulmonary hypertension confirmed by clinical presentation and mean pulmonary artery pressure \>30 mmHg measured by echocardiography at altitude of residence. * healthy subjects (high altitude controls) * Both genders * Age \>16 y * Kyrgyz ethnicity * born, raised and currently living at \>2500 m * healthy subjects currently living at \<1000 m (low altitude controls)
Exclusion criteria
* Pulmonary hypertension from other causes, in particular from left ventricular failure as judged clinically and by echocardiography * Excessive erythrocytosis * Other coexistent disorders that may interfere with the cardio-respiratory system and sleep * Regular use of medication that affects control of breathing * Heavy smoking
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in pulmonary artery pressure | Year 2012 to 2017 | Difference in the change in mean pulmonary artery pressure (mPAP measured by echocardiography) 2012 to 2017 in highlanders with high altitude pulmonary hypertension, healthy highlanders and healthy lowlander |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Survival | Year 2012 to 2017 | Cumulative incidence of death and relocation to lower altitudes between 2012 to 2017 in highlanders with high altitude pulmonary hypertension, healthy highlanders and healthy lowlander |
| Progression of oxygen desaturation index | Year 2012 to 2017 | Difference in the change in the oxygen desaturation index 2012 to 2017 in highlanders with high altitude pulmonary hypertension, healthy highlanders and healthy lowlander |
| Progression of quality of life | Year 2012 to 2017 | Difference in the change in the mental and physical component score of the SF-36 questionnaire 2012 to 2017 in highlanders with high altitude pulmonary hypertension, healthy highlanders and healthy lowlander |
| Changes in nocturnal arterial oxygen saturation | Year 2012 to 2017 | Difference in the change in the nocturnal arterial oxygen saturation 2012 to 2017 in highlanders with high altitude pulmonary hypertension, healthy highlanders and healthy lowlander |
| Exercise performance | Year 2012 to 2017 | Difference in the change in 6 minute walk distance 2012 to 2017 in highlanders with high altitude pulmonary hypertension, healthy highlanders and healthy lowlander |
| Arterial blood gas analysis | Year 2012 to 2017 | Difference in the change in arterial blood gases 2012 to 2017 in highlanders with high altitude pulmonary hypertension, healthy highlanders and healthy lowlander |
| Progression of cognitive performance | Year 2012 to 2017 | Difference in the change in the mean reaction time 2012 to 2017 in highlanders with high altitude pulmonary hypertension, healthy highlanders and healthy lowlander |
Countries
Kyrgyzstan
Outcome results
None listed